Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01ZRI
|
||||
| Former ID |
DCL000353
|
||||
| Drug Name |
Axitinib
|
||||
| Synonyms |
AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Advanced renal cell carcinoma [ICD9: 189; ICD10:C64] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H18N4OS
|
||||
| InChI |
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
|
||||
| InChIKey |
RITAVMQDGBJQJZ-FMIVXFBMSA-N
|
||||
| CAS Number |
CAS 319460-85-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
11972112, 14804960, 17397371, 26683791, 43041647, 51067393, 56374259, 56459367, 57370217, 71821495, 85246173, 92718920, 99004612, 99431770, 114525306, 118844929, 123098392, 124756928, 124950168, 125163735, 126621224, 126647931, 126666999, 131465099, 134339005, 134964394, 135236613, 135697692, 135727420, 136368079, 136920276, 137006067, 137255399, 140075950, 144075334, 144115649, 144207146, 152042317, 152258076, 152344032, 160645509, 160646915, 162011700, 162037379, 162112056, 162164950, 162170729, 163395346, 164041895, 164833257
|
||||
| SuperDrug ATC ID |
L01XE17
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| Integrin cell surface interactions | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated cell proliferation | |||||
| WikiPathways | Focal Adhesion | ||||
| Nifedipine Activity | |||||
| Cardiac Progenitor Differentiation | |||||
| Signaling by VEGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | ||||
| REF 2 | Axitinib: VEGF inhibition in advanced thyroid cancer. Lancet Oncol. 2014 Jul;15(8):e310. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5659). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.